Wegovy maker Novo Nordisk has cut a U.S. sales team focused on obesity and diabetes education for healthcare providers, ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Medicare and Medicaid coverage of GLP-1 weight loss drugs could be just what the doctor ordered for these two struggling ...

Novo Nordisk's shares rose by 5.4% on Thursday as investors turned more positive about the Danish drugmaker's prospects ...

Novo Nordisk A/S rose the most in a month after its diabetes blockbuster Ozempic beat Eli Lilly & Co.’s older drug Trulicity ...

Wegovy has been a hugely popular treatment since the Food and Drug Administration (FDA) approved it for weight loss in ...

Novo Nordisk is “no longer the elephant in the room,” analysts led by Kerry Holford said as they upgraded the stock to Buy ...

In a study with people with Type 2 diabetes and cardiovascular disease, the drug Ozempic was shown to reduce the risk of ...

The drug, which is meant to treat Type 2 diabetes, was compared with Novo Nordisk’s oral semaglutide, and showed greater ...

Letters from the FDA targeted over 100 companies, saying multiple drug firms are pushing “false or misleading” claims about ...

Get the latest healthcare market updates, stock performance, and key pharma news, including Trump’s drug price push and major ...

The FDA's warnings to Eli Lilly, Novo Nordisk and Hims & Hers spotlight risks for ETFs tied to the weight-loss drug boom.